Jincheng Pharm(SZ:300233) Xin Lang Zheng Quan·2025-11-24 01:48Core Viewpoint - Jincheng Pharmaceutical's stock has shown a significant increase of 41.23% year-to-date, despite recent declines in the last five, twenty, and sixty trading days [1][2]. Company Overview - Jincheng Pharmaceutical, established on January 12, 2004, and listed on June 22, 2011, is located in Zibo City, Shandong Province. The company specializes in the research, production, and sales of pharmaceutical intermediates, active pharmaceutical ingredients, and finished formulations [2]. - The revenue composition of Jincheng Pharmaceutical includes: 34.59% from formulation products, 26.61% from other pharmaceutical chemical products, 21.88% from cephalosporin side chain active esters, and 16.92% from biopharmaceuticals and specialty APIs [2]. Financial Performance - For the period from January to September 2025, Jincheng Pharmaceutical reported revenue of 1.932 billion yuan, a year-on-year decrease of 23.19%, and a net profit attributable to shareholders of 31.577 million yuan, down 79.10% year-on-year [2]. - The company has distributed a total of 933 million yuan in dividends since its A-share listing, with 323 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, Jincheng Pharmaceutical had 26,700 shareholders, an increase of 0.46% from the previous period, with an average of 13,903 circulating shares per shareholder, a decrease of 0.46% [2][3]. - Notable shareholders include the fourth-largest shareholder, Fortune Precision Medical Flexible Allocation Mixed A, holding 4.961 million shares, and the eighth-largest shareholder, Hong Kong Central Clearing Limited, holding 3.336 million shares, which decreased by 2.135 million shares from the previous period [3].